Shockwave Therapy Success Rates by Condition

Clinic websites love to advertise “90% success rates” for shockwave therapy. But what does that number actually mean? When you dig into the clinical research, the picture is more nuanced – and more honest – than a single percentage suggests. Understanding how shockwave therapy success rates are measured and reported helps you set realistic expectations before starting treatment.

What “Success” Means in Clinical Trials

Before comparing numbers, you need to know how researchers define a successful outcome. It is rarely “complete pain elimination.”

Most extracorporeal shockwave therapy (ESWT) studies use one or more of these outcome measures:

• Visual Analog Scale (VAS) pain reduction – a 50% or greater drop in pain score is the most common success threshold
• Functional outcome scores – condition-specific questionnaires like the Roles and Maudsley score, VISA-A (for Achilles tendinopathy), or the DASH score (for upper extremity conditions)
• Patient satisfaction – a self-reported “good” or “excellent” rating
• Return to activity – resuming sport or daily activities without significant limitation

A patient who drops from 8/10 pain to 3/10 would count as a success in most studies. So would someone who goes from being unable to walk in the morning to walking with mild discomfort. That is a meaningful clinical improvement – but it is not the same as “cured.”

Success Rates by Condition

The strongest evidence for ESWT comes from chronic tendinopathies that have not responded to conservative treatment. Here is what the data shows across conditions:

Plantar fasciitis: Clinical trials report success rates of 60-80% for chronic cases (those lasting 6+ months and not responding to conventional treatment). A landmark multicenter trial found that 56% of ESWT patients met the primary endpoint versus 28% in the placebo group at 12 weeks (Gerdesmeyer et al., 2008, American Journal of Sports Medicine). Longer follow-up studies show even better numbers, with improvement continuing for 6-12 months after treatment. For more detail on shockwave therapy for plantar fasciitis, see our condition page.

Tennis elbow (lateral epicondylitis): Evidence here is more mixed, with success rates ranging from 65-80% in positive trials. A systematic review found ESWT superior to placebo for pain reduction at 12 weeks, though the magnitude of benefit varied by study protocol (Rompe et al., 2007, Journal of Orthopaedic Research).

Calcific shoulder tendinitis: This is arguably ESWT’s strongest indication. Calcium resorption rates of 70-90% have been reported with focused shockwave therapy, and pain improvement tends to follow. Studies show focused ESWT can break down calcium deposits that cause impingement and pain in the rotator cuff.

Achilles tendinopathy: Success rates of 60-75% are typical, though results differ between insertional and midportion Achilles tendinopathy. Midportion Achilles tendinopathy tends to respond somewhat better.

Patellar tendinopathy: Evidence suggests 50-70% success rates for shockwave therapy for patellar tendinopathy, though this condition has fewer large RCTs than plantar fasciitis or tennis elbow.

Why Numbers Vary So Widely

If you read five different studies on ESWT for the same condition, you might get five different success rates. That is not because the research is unreliable – it is because studies differ in several key ways:

Device type. Focused ESWT and radial pressure wave therapy deliver energy differently and may produce different outcomes for certain conditions.

Treatment protocol. Number of sessions (1-6), energy levels, total impulse count, and session spacing all vary between studies. There is no universally standardized protocol.

Patient selection. Some studies include patients who have had symptoms for 3 months, others require 12 months. Patients who have failed multiple prior treatments may be harder to treat than earlier-stage patients.

Outcome measures. A study using a 50% VAS reduction threshold will report lower success rates than one using a 30% threshold.

Follow-up duration. ESWT benefits can take 3-6 months to fully materialize. Studies with short follow-up periods (4-8 weeks) may underestimate effectiveness.

A More Honest Metric: Number Needed to Treat

Some researchers report the number needed to treat (NNT), which tells you how many patients must be treated for one additional patient to benefit beyond what placebo would achieve. For ESWT:

• Plantar fasciitis NNT is approximately 3-5, meaning for every 3-5 patients treated, one achieves meaningful improvement that would not have occurred with a sham procedure
• Calcific tendinitis NNT is approximately 2-3 for calcium resorption, making it one of the most responsive conditions

For context, many widely accepted medical treatments have NNTs in the 5-10 range. An NNT of 3-5 is considered clinically significant.

Limitations Worth Knowing

The ESWT evidence base has real gaps that affect how confidently we can interpret success rates:

• Small sample sizes. Many RCTs include 30-80 patients per group, limiting statistical power.
• Sham control challenges. Creating a convincing placebo for shockwave therapy is difficult because patients can feel the impulses. Some sham protocols may not be truly inert.
• Short follow-up. Many studies track outcomes for 3-6 months. Fewer track patients for 1-2 years.
• Publication bias. Studies showing positive results are more likely to be published than negative ones.

These limitations do not invalidate the evidence, but they do mean you should interpret any specific success percentage as an approximation rather than a guarantee. Talk with a qualified provider who can discuss how these numbers apply to your specific situation.

The Bottom Line

Shockwave therapy success rates of 60-80% for chronic tendinopathies are supported by clinical evidence, but “success” typically means significant improvement rather than complete resolution. The strongest evidence exists for plantar fasciitis, calcific shoulder tendinitis, and lateral epicondylitis. Your individual outcome depends on your specific condition, its chronicity, the device and protocol used, and your overall health.

When a clinic quotes success rates, ask what study they are citing, how success was defined, and what follow-up period was used. That conversation tells you more than any single number.

Explore our complete guide to conditions treated with shockwave therapy to learn more about the evidence for your specific condition.

References

1. Gerdesmeyer L, Frey C, Vester J, et al. Radial extracorporeal shock wave therapy is safe and effective in the treatment of chronic recalcitrant plantar fasciitis. Am J Sports Med. 2008;36(11):2100-2109. PubMed

2. Rompe JD, Maffulli N. Repetitive shock wave therapy for lateral elbow tendinopathy (tennis elbow): a systematic and qualitative analysis. Br Med Bull. 2007;83:355-378. PubMed

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Shockwave therapy outcomes vary by individual and condition. Consult a qualified healthcare provider to determine if shockwave therapy is appropriate for your situation.